M

Microba Life Sciences Ltd
ASX:MAP

Watchlist Manager
Microba Life Sciences Ltd
ASX:MAP
Watchlist
Price: 0.09 AUD -2.17% Market Closed
Market Cap: 40.3m AUD
Section:
Wall Street Price Targets
Wall Street Price Targets
Revenue Forecast
Operating Income Forecast
Net Income Forecast
See Also
Price Target
Loading...
Revenue
Loading...
Operating Income
Loading...
Net Income
Loading...

Wall Street
Price Targets

MAP Price Targets Summary
Microba Life Sciences Ltd

Wall Street analysts forecast MAP stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for MAP is 0.29 AUD with a low forecast of 0.26 AUD and a high forecast of 0.34 AUD.

MAP Lowest Forecast
Wall Street Target
0.26 AUD
192% Upside
MAP Average Forecast
Wall Street Target
0.29 AUD
217% Upside
MAP Highest Forecast
Wall Street Target
0.34 AUD
273% Upside
Lowest
Price Target
0.26 AUD
192% Upside
Average
Price Target
0.29 AUD
217% Upside
Highest
Price Target
0.34 AUD
273% Upside
Microba Life Sciences Ltd Competitors:
Price Targets
HIMS
Hims & Hers Health Inc
1% Downside
KRSNAA
Krsnaa Diagnostics Ltd
27% Upside
A
AND
Andlauer Healthcare Group Inc
6% Upside
VIJAYA
Vijaya Diagnostic Centre Ltd
5% Upside
HIMS
Hims & Hers Health Inc
1% Downside
KRSNAA
Krsnaa Diagnostics Ltd
27% Upside
A
AND
Andlauer Healthcare Group Inc
6% Upside
VIJAYA
Vijaya Diagnostic Centre Ltd
5% Upside
603882
Guangzhou Kingmed Diagnostics Group Co Ltd
5% Upside
PRVA
Privia Health Group Inc
51% Upside
LALPATHLAB
Dr. Lal PathLabs Ltd
6% Upside
V3V
Vita 34 AG
34% Upside

Revenue
Forecast

Revenue Estimate
Microba Life Sciences Ltd

For the last 4 years the compound annual growth rate for Microba Life Sciences Ltd's revenue is 43%. The projected CAGR for the next 3 years is 32%.

43%
Past Growth
32%
Estimated Growth
Estimates Accuracy
0%
Average Miss
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
Microba Life Sciences Ltd

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
21%
Average Beat
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
Microba Life Sciences Ltd

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-32%
Average Miss
What are analyst estimates?

See Also

Summary
MAP intrinsic value, competitors valuation, and company profile.
DCF Valuation
MAP stock valuation using Discount Cash Flow valuation method.
Relative Valuation
MAP stock valuation using valuation multiples.
Wall Street Estimates
MAP price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
MAP stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is MAP's stock price target?
Price Target
0.29 AUD

According to Wall Street analysts, the average 1-year price target for MAP is 0.29 AUD with a low forecast of 0.26 AUD and a high forecast of 0.34 AUD.

What is Microba Life Sciences Ltd's Revenue forecast?
Projected CAGR
32%

For the last 4 years the compound annual growth rate for Microba Life Sciences Ltd's revenue is 43%. The projected CAGR for the next 3 years is 32%.

Back to Top
ALPHA SPREAD
Follow us
Join more than 268,100+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.